Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
12 févr. 2024 05h30 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
Annual report 2023: ALK delivers 9% sales growth with profits up 50%
08 févr. 2024 07h35 HE
|
ALK Abello
08 February 2024 ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company’s 2023 annual report. Following a robust performance in Q4, full-year results were in line with the...
ALK and McMaster researchers discover new cell that remembers allergies
07 févr. 2024 14h10 HE
|
ALK Abello
Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abelló A/S have made a ground-breaking discovery: a new cell that remembers allergies. The discovery gives...
ALK’s 2030 CO2 reduction targets have been approved by SBTi
05 févr. 2024 03h30 HE
|
ALK Abello
ALK’s near-term carbon reduction targets for scope 1, 2 and 3 have been validated and approved by the Science Based Targets initiative. Today, ALK announces that its near-term carbon reduction...
Dato for offentliggørelse af årsrapport for 2023 for ALK og webcast
31 janv. 2024 03h44 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør årsrapport for 2023 torsdag den 8. februar 2024 om eftermiddagen. ALK afholder samme dag kl. 16.00 (CET) en telekonference for investorer og...
Release date of annual report 2023 for ALK and webcast
31 janv. 2024 03h44 HE
|
ALK Abello
On Thursday, 8 February 2024 in the afternoon, ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its annual report for 2023. ALK will host an online meeting for analysts and institutional investors...
ALK’s europæiske registreringsansøgning for tabletvaccine mod husstøvmideallergi hos børn accepteret til vurdering
25 janv. 2024 07h15 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) meddelte i dag, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn er accepteret til vurdering af de...
ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review
25 janv. 2024 07h15 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ACARIZAX® (house dust mite sublingual immunotherapy tablet) in young children has been accepted for review by...
ALK afslutter første del af fase 1-studie med peanuttablet
18 janv. 2024 09h34 HE
|
ALK Abello
Studiet fortsætter nu i sin anden del, som forventes afsluttet senere i 2024.ALK indsender protokolændring for at udvide studiet til et fase 1-2 effektstudie. ALK (ALKB:DC / OMX: ALK B / AKBLF)...
ALK completes first part of phase 1 trial with peanut SLIT-tablet
18 janv. 2024 09h34 HE
|
ALK Abello
The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK (ALKB:DC / OMX: ALK B /...